- CYD-TDV (Dengvaxia)
- DENVax
- TetraVax-DV
- Others
Dengue Vaccine Market size was valued at USD 361 million in 2022 and is expected to reach a value of USD 1096.48 million by 2028, growing at a significant CAGR of 17.2% from 2023-2029. As per the World Health Organization, the frequency of dengue has become significant over ongoing many years. A larger part of the cases are asymptomatic, gentle or independent, and thus the genuine number of diseases are exceptionally under-announced. One displaying gauge demonstrates 390 million dengue diseases each year (95% valid span 284-528 million), of which 96 million show clinically. This report studies market dynamics elaborately to identify the current trends & drivers, future opportunities, and possible challenges to the key stakeholders operating in the market. In addition, dengue vaccines market report covers newer product introductions and competition analysis with a vividly illustrated competition dashboard to assess the market competition. Moreover, PBI analyzed market to better equip clients with possible investment opportunities across the regions (Regional Investment Hot-Spots) and market unmet needs (Product Opportunities). Key stakeholders of the dengue vaccine market report include suppliers, manufacturers, marketers, policymakers engaged in manufacturing and supply of dengue vaccine.
Global Dengue Vaccine Market Summary
Study Period
2023-29
Base Year
2022
CAGR
17.2%
Largest Market
Asia Pacific
Fastest Growing Market
Latin America
Dengue Vaccine Market Dynamics
Dengue fever or breakbone fever is caused by four distinct, virus serotypes, which are transmitted to humans by Aedes aegypti mosquito. Dengue fever is epidemic in several countries of Asia-pacific and Latin America region. The growing global epidemic of dengue in aforementioned regions is expected to create demand for the dengue vaccine over the forecast period. Increasing initiatives from local governments and World Health Organization (WHO) to curb the dengue menace across the regions expected to drive the market demand for dengue vaccine over the forecast period. Moreover, several governments are actively looking for incorporating dengue vaccine in routine immunization programmes to prevent the dengue epidemics. According to WHO estimates, there are around 50 Mn dengue infections worldwide every year and dengue is endemic in over 100 countries across the globe.
Asia-Pacific Got Significant Share
Dengue Vaccine Market-Regional Analysis
Asia-Pacific region expected to lead the global dengue vaccines market owing to widespread prevalence and incidence of dengue fever and large population, who are at dengue fever risk. Latin America expected to register highest market growth among all regions owing to the early adoption of the vaccine in government immunization programmes.
Latin America
Europe
Asia Pacific
Middle East
North America
Key Features of the Reports
- The report provides granular level information about the market size, regional market share, historic market (2018 to 2022) and forecast (2023 to 2029)
- The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
- The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
- The report tracks recent innovations, key developments and startup’s details that are actively working in the market
- The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
- The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market
Global Dengue Vaccine Market Segmentation
By Product Type
By Vaccine Type
- Live Attenuated Vaccine
- Killed Vaccine
- Others
By End Users
- Hospitals
- Clinics
- Government Institutes
- Non-Governmental Organization (NGOs)
By Geography
- North America
- Latin America
- Europe
- Asia Pacifc
- MIddle East and Africa
Frequently Asked Questions
The Dengue vaccine market size was valued at USD 361 million in 2022.
The Dengue vaccine market has been classified into North America, Asia Pacific, Europe, Latin America, Middle East and Africa, and the rest of MEA.
The Dengue vaccine market key players Takeda Pharmaceutical Company Limited, Serum Institute of India Pvt. Ltd, Panacea Biotec Limited, Sanofi Pasteur Limited, GeneOne Life Science, Sun Pharmaceutical Industries Ltd.
| 1. Executive Summary |
| 2. Global Dengue Vaccine Market Introduction |
| 2.1. Global Dengue Vaccine Market Taxonomy |
| 2.2. Global Dengue Vaccine Market Definitions |
| 2.2.1. By Product Type |
| 2.2.2. By Vaccine Type |
| 2.2.3. By End User |
| 2.2.4. By Region |
| 3. Global Dengue Vaccine Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Global Dengue Vaccine Market Dynamic Factors - Impact Analysis |
| 3.6. Global Dengue Vaccine Market Competition Landscape |
| 4. Global Dengue Vaccine Market Analysis, 2018-2022 and Forecast, 2023-2029 |
| 4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn) |
| 4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3. Market Opportunity Analysis |
| 5. Global Dengue Vaccine Market, By Product Type, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn) |
| 5.1. CYD-TDV (Dengvaxia) |
| 5.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn) |
| 5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3. Market Opportunity Analysis |
| 5.2. DENVax |
| 5.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn) |
| 5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3. Market Opportunity Analysis |
| 5.3. TetraVax-DV |
| 5.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn) |
| 5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.3. Market Opportunity Analysis |
| 5.4. Others |
| 5.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn) |
| 5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.4.3. Market Opportunity Analysis |
| 6. Global Dengue Vaccine Market, By Vaccine Type, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn) |
| 6.1. Live Attenuated Vaccine |
| 6.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn) |
| 6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. Killed Vaccine |
| 6.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn) |
| 6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 6.3. Others |
| 6.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn) |
| 6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.3.3. Market Opportunity Analysis |
| 7. Global Dengue Vaccine Market Forecast, By End User, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn) |
| 7.1. Hospitals |
| 7.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn) |
| 7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.1.3. Market Opportunity Analysis |
| 7.2. Clinics |
| 7.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn) |
| 7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.2.3. Market Opportunity Analysis |
| 7.3. Government Institutes |
| 7.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn) |
| 7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.3.3. Market Opportunity Analysis |
| 7.4. Non-Governmental Organizations (NGOs) |
| 7.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn) |
| 7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.4.3. Market Opportunity Analysis |
| 8. Global Dengue Vaccine Market Forecast, By Region, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn) |
| 8.1. North America |
| 8.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn) |
| 8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.1.3. Market Opportunity Analysis |
| 8.2. Europe |
| 8.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn) |
| 8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.2.3. Market Opportunity Analysis |
| 8.3. Asia-Pacific |
| 8.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn) |
| 8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.3.3. Market Opportunity Analysis |
| 8.4. Latin America |
| 8.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn) |
| 8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.4.3. Market Opportunity Analysis |
| 8.5. Middle East and Africa |
| 8.5.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn) |
| 8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.5.3. Market Opportunity Analysis |
| 8.6. Global Dengue Vaccine Market - Opportunity Analysis Index, By Product Type, By Application, By End User, and Region, 2023-2029 |
| 9. North America Dengue Vaccine Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn) |
| 9.1. Product Type Analysis 2018-2022 and Forecast 2023-2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 9.1.1. CYD-TDV (Dengvaxia) |
| 9.1.2. DENVax |
| 9.1.3. TetraVax-DV |
| 9.1.4. Others |
| 9.2. Vaccine Type Analysis 2018-2022 and Forecast 2023-2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 9.2.1. Live Attenuated Vaccine |
| 9.2.2. Killed Vaccine |
| 9.2.3. Others |
| 9.3. End User Analysis 2018-2022 and Forecast 2023-2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 9.3.1. Hospitals |
| 9.3.2. Clinics |
| 9.3.3. Government Institutes |
| 9.3.4. Non-Governmental Organizations (NGOs) |
| 9.4. Country Analysis 2018-2022 and Forecast 2023-2029 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
| 9.4.1. USA |
| 9.4.2. Canada |
| 9.5. North America Dengue Vaccine Market - Opportunity Analysis Index, By Product Type, By Vaccine Type, By End User and Country, 2023-2029 |
| 9.6. North America Dengue Vaccine Market Dynamics Trends |
| 10. Europe Dengue Vaccine Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn) |
| 10.1. Product Type Analysis 2018-2022 and Forecast 2023-2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 10.1.1. CYD-TDV (Dengvaxia) |
| 10.1.2. DENVax |
| 10.1.3. TetraVax-DV |
| 10.1.4. Others |
| 10.2. Vaccine Type Analysis 2018-2022 and Forecast 2023-2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 10.2.1. Live Attenuated Vaccine |
| 10.2.2. Killed Vaccine |
| 10.2.3. Others |
| 10.3. End User Analysis 2018-2022 and Forecast 2023-2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 10.3.1. Hospitals |
| 10.3.2. Clinics |
| 10.3.3. Government Institutes |
| 10.3.4. Non-Governmental Organizations (NGOs) |
| 10.4. Country Analysis 2018-2022 and Forecast 2023-2029 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
| 10.4.1. Germany |
| 10.4.2. UK |
| 10.4.3. France |
| 10.4.4. Spain |
| 10.4.5. Italy |
| 10.4.6. Russia |
| 10.4.7. Benelux |
| 10.4.8. Rest of Europe |
| 10.5. Europe Dengue Vaccine Market - Opportunity Analysis Index, By Product Type, By Vaccine Type, By End User and Country, 2023-2029 |
| 10.6. Europe Dengue Vaccine Market Dynamics Trends |
| 11. Asia-Pacific Dengue Vaccine Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn) |
| 11.1. Product Type Analysis 2018-2022 and Forecast 2023-2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 11.1.1. CYD-TDV (Dengvaxia) |
| 11.1.2. DENVax |
| 11.1.3. TetraVax-DV |
| 11.1.4. Others |
| 11.2. Vaccine Type Analysis 2018-2022 and Forecast 2023-2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 11.2.1. Live Attenuated Vaccine |
| 11.2.2. Killed Vaccine |
| 11.2.3. Others |
| 11.3. End User Analysis 2018-2022 and Forecast 2023-2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 11.3.1. Hospitals |
| 11.3.2. Clinics |
| 11.3.3. Government Institutes |
| 11.3.4. Non-Governmental Organizations (NGOs) |
| 11.4. Country Analysis 2018-2022 and Forecast 2023-2029 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
| 11.4.1. China |
| 11.4.2. India |
| 11.4.3. Japan |
| 11.4.4. ASEAN |
| 11.4.5. Australia & New Zealand |
| 11.4.6. Rest of Asia-Pacific |
| 11.5. Asia-Pacific Dengue Vaccine Market - Opportunity Analysis Index, By Product Type, By Vaccine Type, By End User and Country, 2023-2029 |
| 11.6. Asia-Pacific Dengue Vaccine Market Dynamics Trends |
| 12. Latin America Dengue Vaccine Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn) |
| 12.1. Product Type Analysis 2018-2022 and Forecast 2023-2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 12.1.1. CYD-TDV (Dengvaxia) |
| 12.1.2. DENVax |
| 12.1.3. TetraVax-DV |
| 12.1.4. Others |
| 12.2. Vaccine Type Analysis 2018-2022 and Forecast 2023-2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 12.2.1. Live Attenuated Vaccine |
| 12.2.2. Killed Vaccine |
| 12.2.3. Others |
| 12.3. End User Analysis 2018-2022 and Forecast 2023-2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 12.3.1. Hospitals |
| 12.3.2. Clinics |
| 12.3.3. Government Institutes |
| 12.3.4. Non-Governmental Organizations (NGOs) |
| 12.4. Country Analysis 2018-2022 and Forecast 2023-2029 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
| 12.4.1. Brazil |
| 12.4.2. Mexico |
| 12.4.3. Argentina |
| 12.4.4. Rest of Latin America |
| 12.5. Latin America Dengue Vaccine Market - Opportunity Analysis Index, By Product Type, By Vaccine Type, By End User and Country, 2023-2029 |
| 12.6. Latin America Dengue Vaccine Market Dynamics Trends |
| 13. Middle East and Africa Dengue Vaccine Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn) |
| 13.1. Product Type Analysis 2018-2022 and Forecast 2023-2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 13.1.1. CYD-TDV (Dengvaxia) |
| 13.1.2. DENVax |
| 13.1.3. TetraVax-DV |
| 13.1.4. Others |
| 13.2. Vaccine Type Analysis 2018-2022 and Forecast 2023-2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 13.2.1. Live Attenuated Vaccine |
| 13.2.2. Killed Vaccine |
| 13.2.3. Others |
| 13.3. End User Analysis 2018-2022 and Forecast 2023-2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 13.3.1. Hospitals |
| 13.3.2. Clinics |
| 13.3.3. Government Institutes |
| 13.3.4. Non-Governmental Organizations (NGOs) |
| 13.4. Country Analysis 2018-2022 and Forecast 2023-2029 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
| 13.4.1. Gulf Cooperation Council (GCC) Countries |
| 13.4.2. Israel |
| 13.4.3. South Africa |
| 13.4.4. Rest of MEA |
| 13.5. MEA Dengue Vaccine Market - Opportunity Analysis Index, By Product Type, By Vaccine Type, By End User and Country, 2023-2029 |
| 13.6. MEA Dengue Vaccine Market Dynamics Trends |
| 14. Competition Landscape |
| 14.1. Strategic Dashboard of Top Market Players |
| 14.2. Company Profiles (Introduction, Financial Analysis, Offerings, Key Developments, Strategies, and SWOT Analysis) |
| 14.2.1. Takeda Pharmaceutical Company Limited |
| 14.2.2. Serum Institute of India Pvt. Ltd |
| 14.2.3. Panacea Biotec Limited |
| 14.2.4. Sanofi Pasteur Limited |
| 14.2.5. GeneOne Life Science |
| 14.2.6. Sun Pharmaceutical Industries Ltd. |
| 15. Research Methodology |
| 16. Key Assumptions and Acronyms |
- Takeda Pharmaceutical Company Limited
- Serum Institute of India Pvt. Ltd
- Panacea Biotec Limited
- Sanofi Pasteur Limited
- GeneOne Life Science
- Sun Pharmaceutical Industries Ltd.